Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation
NCT00030186
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
Leukemia, Myeloid
Interventions
DRUG:
CEP-701 60mg
DRUG:
Cep-701 80mg
DRUG:
Cep-701 40mg
Sponsor
Cephalon